ESG Information

Our diversified product portfolio includes long-established brand and niche products. We are present with our products in 145 countries worldwide. Our geographical diversification not only reduces our dependence on individual markets and thus also sales risks, but also gives people in many regions access to medicines, some of which are indispensable. About one third of our medicines are on the World Health Organisation's Model List of Essential Medicines, which means that they are among the most urgently needed medicines for health care and are therefore indispensable globally.

The quality and safety of our products is ensured through regular safety audits and extensive training for our employees. 

In addition, CHEPLAPHARM has committed to Good Distribution Practices (GDP) for the pharmaceutical industry. These describe minimum standards to ensure that the quality and integrity of medicinal products is guaranteed throughout the supply chain. For this purpose, CHEPLAPHARM has adopted so-called Standard Operating Procedures (SOP), which define the standardised procedure for the distribution of medicinal products.

Our products are manufactured and distributed externally. The size of the companies in our supply chain ranges from smaller local contract service providers to large international pharmaceutical groups.

The majority of our partners are located in Europe and abroad and are therefore largely subject to European law, which places particularly high demands on the quality and sustainability of pharmaceutical products.

We have initiated a first, central part of this sustainability process by establishing a regular and, if possible, complete survey of our supply chain. With this survey, we collect information on the fulfilment of relevant sustainability standards as well as on current sustainability measures and goals. 

Even though we are only at the beginning of systematically recording our ecological footprint, we want to integrate sustainability-relevant considerations much more strongly into our corporate activities in the future. We are currently establishing an environmental and energy management system that is to be certified according to ISO 14001 in 2023. In addition to the identification and control of our environmental impacts, this also provides for the measurable improvement of our environmental compatibility.

In 2021, renewable energies accounted for 65% of CHEPLAPHARM's total electricity consumption.

The main energy source for our heat supply is gas, from which we cover 90% of our needs.

CHEPLAPHARM makes an important contribution to people's health and well-being. CHEPLAPHARM's products meet the high regulatory requirements for safety and quality. Of elementary importance here is the security of supply through a significant diversification of producers, the establishment of second sources and sophisticated storage processes in order to be able to provide sufficient medicines at all times.

As a large employer in the Greifswald region, we are aware of our special responsibility for this structurally weak region. The active and targeted further training of our employees is particularly close to our hearts. Joint activities strengthen team cohesion and promote motivation and commitment.

CHEPLAPHARM's greatest potential in achieving this goal lies in making processes along the value chain more energy and resource efficient and reducing emissions and waste in production. Our impact is aimed in particular at our supply chain, which we also continuously analyse for sustainability aspects.

Climate protection requires a continuous and long-term approach. We can make a particularly large contribution to climate protection via our supply chain by incorporating climate protection into all processes and obliging our supplier companies to comply with minimum requirements relevant to climate protection. At our site in Greifswald, we actively contribute to climate protection with our own photovoltaic system, charging stations for e-cars that can be used free of charge, and the construction of a new low-energy building.